BNY Mellon High Yield Beta ETF (BKHY) NPORT-P BNY Mellon Innovators ETF (May 2024 report)

STATEMENT

OF

INVESTMENTS

May

31,

2024

(Unaudited)

1

Description

Shares

Value

($)

Common

Stocks

–

99.0%

Banks

–

1.0%

JPMorgan

Chase

&

Co.

717

145,286

Consumer

Discretionary

Distribution

&

Retail

–

0.8%

Chewy,

Inc.,

Class

A

(a)

5,347

113,410

Consumer

Durables

&

Apparel

–

2.8%

Garmin

Ltd.

741

121,413

Lululemon

Athletica,

Inc.

(a)

879

274,239

395,652

Consumer

Services

–

2.8%

Airbnb,

Inc.,

Class

A

(a)

1,579

228,845

DraftKings,

Inc.,

Class

A

(a)

4,986

175,158

404,003

Energy

–

2.3%

Cactus,

Inc.,

Class

A

(b)

6,429

330,129

Financial

Services

–

3.7%

Ares

Management

Corp.,

Class

A

1,733

242,915

Block,

Inc.,

Class

A

(a)

4,531

290,346

533,261

Food,

Beverage

&

Tobacco

–

7.7%

Celsius

Holdings,

Inc.

(a)(b)

4,537

362,869

Freshpet,

Inc.

(a)

3,212

421,318

Vital

Farms,

Inc.

(a)

7,677

317,674

1,101,861

Health

Care

Equipment

&

Services

–

15.3%

Accolade,

Inc.

(a)

4,625

32,745

Align

Technology,

Inc.

(a)

1,582

406,906

DexCom,

Inc.

(a)

3,478

413,082

Guardant

Health,

Inc.

(a)

6,105

165,446

Inspire

Medical

Systems,

Inc.

(a)

1,583

251,365

Intuitive

Surgical,

Inc.

(a)

740

297,569

iRhythm

Technologies,

Inc.

(a)

1,549

136,637

Outset

Medical,

Inc.

(a)

8,504

31,720

Privia

Health

Group,

Inc.

(a)

6,722

116,761

PROCEPT

BioRobotics

Corp.

(a)

1,103

73,239

TransMedics

Group,

Inc.

(a)

1,843

251,385

2,176,855

Media

&

Entertainment

–

15.2%

Alphabet,

Inc.,

Class

C

(a)

4,692

816,220

Liberty

Media

Corp.-Liberty

Formula

One,

Class

C

(a)

3,079

228,277

Netflix,

Inc.

(a)

838

537,677

Reddit,

Inc.,

Class

A

(a)(b)

5,024

272,502

Trade

Desk,

Inc.

(The),

Class

A

(a)

3,446

319,720

2,174,396

STATEMENT

OF

INVESTMENTS

(continued)

2

Description

Shares

Value

($)

Common

Stocks

–

99.0%

(continued)

Pharmaceuticals,

Biotechnology

&

Life

Sciences

–

18.5%

Alnylam

Pharmaceuticals,

Inc.

(a)

1,180

175,147

Ascendis

Pharma

A/S,

ADR

(a)

2,072

279,927

Crinetics

Pharmaceuticals,

Inc.

(a)

2,414

107,206

Denali

Therapeutics,

Inc.

(a)

5,750

106,720

Illumina,

Inc.

(a)

1,732

180,613

Insmed,

Inc.

(a)

12,284

676,234

Keros

Therapeutics,

Inc.

(a)

2,467

115,628

Natera,

Inc.

(a)

2,075

221,050

Pacific

Biosciences

of

California,

Inc.

(a)

44,058

78,864

Repligen

Corp.

(a)(b)

1,489

221,995

Sarepta

Therapeutics,

Inc.

(a)

1,553

201,673

Twist

Bioscience

Corp.

(a)(b)

4,690

196,511

Xenon

Pharmaceuticals,

Inc.

(a)

1,946

74,084

2,635,652

Real

Estate

Management

&

Development

–

4.0%

CoStar

Group,

Inc.

(a)

7,258

567,358

Semiconductors

&

Semiconductor

Equipment

–

13.3%

NVIDIA

Corp.

1,730

1,896,651

Software

&

Services

–

10.7%

Confluent,

Inc.,

Class

A

(a)

9,613

249,650

DoubleVerify

Holdings,

Inc.

(a)

7,234

131,659

Klaviyo,

Inc.,

Class

A

(a)

6,393

144,737

Monday.com

Ltd.

(a)

549

124,025

MongoDB,

Inc.,

Class

A

(a)

698

164,770

Shopify,

Inc.,

Class

A

(a)

3,752

221,931

Snowflake,

Inc.,

Class

A

(a)

2,411

328,330

Twilio,

Inc.,

Class

A

(a)

2,771

159,055

1,524,157

Technology

Hardware

&

Equipment

–

0.9%

Pure

Storage,

Inc.,

Class

A

(a)

2,001

120,640

Total

Common

Stocks

(cost

$11,266,209)

14,119,311

Investment

Companies

–

1.2%

Registered

Investment

Companies

–

1.2%

Dreyfus

Institutional

Preferred

Government

Money

Market

Fund,

Institutional

Shares,

5.28%

(c)(d)

(cost

$175,766)

175,766

175,766

Investment

of

Cash

Collateral

for

Securities

Loaned

–

0.9%

Registered

Investment

Companies

–

0.9%

Dreyfus

Institutional

Preferred

Government

Money

Market

Fund,

Institutional

Shares,

5.28%

(c)(d)

(cost

$125,873)

125,873

125,873

Total

Investments

(cost

$11,567,848)

101.1%

14,420,950

3

See

Notes

to

Statement

of

Investments

Description

Shares

Value

($)

Investment

of

Cash

Collateral

for

Securities

Loaned

–

0.9%

(continued)

Registered

Investment

Companies

–

0.9%

(continued)

Liabilities,

Less

Cash

and

Receivables

(1.1)%

(157,246)

Net

Assets

100.0%

14,263,704

ADR—American

Depositary

Receipt

(a)

Non-income

producing

security.

(b)

Security,

or

portion

thereof,

on

loan.

At

May

31,

2024,

the

value

of

the

fund’s

securities

on

loan

was

$1,219,122

and

the

value

of

the

collateral

was

$1,231,521,

consisting

of

cash

collateral

of

$125,873

and

U.S.

Government

&

Agency

securities

valued

at

$1,105,648.

In

addition,

the

value

of

collateral

may

include

pending

sales

that

are

also

on

loan.

(c)

Investment

in

affiliated

issuer.

The

investment

objective

of

this

investment

company

is

publicly

available

and

can

be

found

within

the

investment

company’s

prospectus.

(d)

The

rate

shown

is

the

1-day

yield

as

of

May

31,

2024.

NOTES

TO

STATEMENT

OF

INVESTMENTS

(Unaudited)

4

The

Financial

Accounting

Standards

Board

(“FASB”)

Accounting

Standards

Codification

(“ASC”)

is

the

exclusive

reference

of

authoritative

U.S.

generally

accepted

accounting

principles

(“GAAP”)

recognized

by

the

FASB

to

be

applied

by

nongovernmental

entities.

Rules

and

interpretive

releases

of

the

Securities

and

Exchange

Commission

(“SEC”)

under

authority

of

federal

laws

are

also

sources

of

authoritative

GAAP

for

SEC

registrants. BNY

Mellon

Innovators

ETF (the

“fund”)

is an

investment

company

and

applies

the

accounting

and

reporting

guidance

of

the

FASB

ASC

Topic

946

Financial

Services-Investment

Companies. The

fund’s

financial

statements

are

prepared

in

accordance

with

GAAP,

which

may

require

the

use

of

management

estimates

and

assumptions.

Actual

results

could

differ

from

those

estimates.  

(a)

Portfolio

valuation:

The

fair

value

of

a

financial

instrument

is

the

amount

that

would

be

received

to

sell

an

asset

or

paid

to

transfer

a

liability

in

an

orderly

transaction

between

market

participants

at

the

measurement

date

(i.e.,

the

exit

price).

GAAP

establishes

a

fair

value

hierarchy

that

prioritizes

the

inputs

of

valuation

techniques

used

to

measure

fair

value.

This

hierarchy

gives

the

highest

priority

to

unadjusted

quoted

prices

in

active

markets

for

identical

assets

or

liabilities

(Level

1

measurements)

and

the

lowest

priority

to

unobservable

inputs

(Level

3

measurements).

Additionally,

GAAP

provides

guidance

on

determining

whether

the

volume

and

activity

in

a

market

has

decreased

significantly

and

whether

such

a

decrease

in

activity

results

in

transactions

that

are

not

orderly.

GAAP

requires

enhanced

disclosures

around

valuation

inputs

and

techniques

used

during

annual

and

interim

periods.

Various

inputs

are

used

in

determining

the

value

of

the

fund’s

investments

relating

to

fair

value

measurements.

These

inputs

are

summarized

in

the

three

broad

levels

listed

below:

Level

1

—

unadjusted

quoted

prices

in

active

markets

for

identical

investments.

Level

2

—

other

significant

observable

inputs

(including

quoted

prices

for

similar 

investments,

interest

rates,

prepayment

speeds,

credit

risk,

etc.).

Level

3

—

significant

unobservable

inputs

(including

the

fund’s

own

assumptions

in

determining

the

fair

value

of

investments).

The

inputs

or

methodology

used

for

valuing

securities

are

not

necessarily

an

indication

of

the

risk

associated

with

investing

in

those

securities.

Changes

in

valuation

techniques

may

result

in

transfers

in

or

out

of

an

assigned

level

within

the

disclosure

hierarchy.

Valuation

techniques

used

to

value

the

fund’s

investments

are

as

follows:

5

BNY

Mellon

ETF

Trust’s

(the

“Trust”) Board

of

Trustees

(the

“Board”)

has

designated

the

Adviser

as

the

fund’s

valuation

designee

to

make

all

fair

value

determinations

with

respect

to

the

fund’s

portfolio

of

investments,

subject

to

the

Board’s

oversight

and

pursuant

to

Rule

2a-5

under

the

Act.

Investments

in

equity

securities,

including

ETFs

(but

not

including

investments

in

other

open-end

registered

investment

companies),

generally

are

valued

at

the

last

sales

price

on

the

day

of

valuation

on

the

securities

exchange

or

national

securities

market

on

which

such

securities

primarily

are

traded.

Securities

listed

on

the

National

Association

of

Securities

Dealers

Automated

Quotation

System

(“NASDAQ”)

for

which

market

quotations

are

available

will

be

valued

at

the

official

closing

price.

If

there

are

no

transactions

in

a

security,

or

no

official

closing

prices

for

a

NASDAQ

market-listed

security

on

that

day,

the

security

will

be

valued

at

the

average

of

the

most

recent

bid

and

asked

prices.

Bid

price

is

used

when

no

asked

price

is

available.

Open

short

positions

for

which

there

is

no

sale

price

on

a

given

day

are

valued

at

the

lowest

asked

price.

Registered

investment

companies

that

are

not

traded

on

an

exchange

are

valued

at

their

net

asset

value.

All

of

the

preceding

securities

are

generally

categorized

within

Level

1

of

the

fair

value

hierarchy. 

When

market

quotations

or

official

closing

prices

are

not

readily

available,

or

are

determined

not

to

reflect

fair

value

accurately,

they are

valued

at

fair

value

as

determined

in

good

faith

based

on

procedures

approved

by

the

Board.

Fair

value

of

investments

may

be

determined

by

valuation

designee

using

such

information

as

it

deems

appropriate

under

the

circumstances.

Certain

factors

may

be

considered

when

fair

valuing

investments

such

as:

fundamental

analytical

data,

the

nature

and

duration

of

restrictions

on

disposition,

an

evaluation

of

the

forces

that

influence

the

market

in

which

the

securities

are

purchased

and

sold,

and

public

trading

in

similar

securities

of

the

issuer

or

comparable

issuers.

These

securities

are

either

categorized

within

Level

2

or

3

of

the

fair

value

hierarchy

depending

on

the

relevant

inputs

used.

For

securities

where

observable

inputs

are

limited,

assumptions

about

market

activity

and

risk

are

used

and

are

generally

categorized

within

Level

3

of

the

fair

value

hierarchy.

The

table

below

summarizes

the

inputs

used

as

of May

31,

2024

in

valuing

the

fund’s

investments:

NOTES

TO

STATEMENT

OF

INVESTMENTS

(Unaudited)

(continued)

6

Fair

Value

Measurements

Pursuant

to

a

securities

lending

agreement

with

BNY

Mellon,

the

fund

may

lend

securities

to

qualified

institutions.

It

is

the

fund’s

policy

that,

at

origination,

all

loans

are

secured

by

collateral

of

at

least

102%

of

the

value

of

U.S.

securities

loaned

and

105%

of

the

value

of

foreign

securities

loaned.

Collateral

equivalent

to

at

least

100%

of

the

market

value

of

securities

on

loan

is

maintained

at

all

times.

Collateral

is

either

in

the

form

of

cash,

which

can

be

invested

in

certain

money

market

mutual

funds

managed

by

the

Adviser,

or

U.S.

Government

and

Agency

securities.

The

fund

is

entitled

to

receive

all

dividends,

interest

and

distributions

on

securities

loaned,

in

addition

to

income

earned

as

a

result

of

the

lending

transaction.

Should

a

borrower

fail

to

return

the

securities

in

a

timely

manner,

The

Bank

of

New

York

Mellon

is

required

to

replace

the

securities

for

the

benefit

of

the

fund

or

credit

the

fund

with

the

market

value

of

the

unreturned

securities

and

is

subrogated

to

the

fund’s

rights

against

the

borrower

and

the

collateral.

Additionally,

the

contractual

maturity

of

security

lending

transactions

are

on

an

overnight

and

continuous

basis.

Additional

investment

related

disclosures

are

hereby

incorporated

by

reference

to

the

annual

and

semi-annual

reports

previously

filed

with

the

SEC

on

Form

N-

CSR.

Additional

investment

related

disclosures

are

hereby

incorporated

by

reference

to

the

annual

and

semi-annual

reports

previously

filed

with

the

SEC

on

Form

N-CSR.

At May

31,

2024,

accumulated

net

unrealized

appreciation on

investments

was

$2,853,102,

consisting

of

gross

appreciation

of

$4,131,790

and

gross

depreciation

of

$1,278,688.

At

May

31,

2024,

the

cost

of

investments

for

federal

income

tax

purposes

was

substantially

the

same

as

the

cost

for

financial

reporting

purposes

(see

the

Statement

of

Investments).

Level

1

-

Unadjusted

Quoted

Prices

Level

2

-

Other

Significant

Observable

Inputs

Level

3

-

Significant

Unobservable

Inputs

Total

Assets

($)

Investments

In

Securities:

†

Common

Stocks

14,119,311

—

—

14,119,311

Investment

Companies

175,766

—

—

175,766

Investment

of

Cash

Collateral

for

Securities

Loaned

125,873

—

—

125,873

†

See

Statement

of

Investments

for

additional

detailed

categorizations,

if

any.